Levofloxacin for the Treatment of Community-Acquired Pneumonia in the US Based on the Latest Treatment Guidelines
John G Bartlett, MD
Johns Hopkins University, School of Medicine, Baltimore, Maryland, USA
Lower respiratory infections are the major cause of death due to infectious diseases in the United States. It is also one of the fastest moving fields of medicine in terms of changes in treatment strategies, new discoveries and controversies. In an effort to maintain currency, the Infectious Diseases Society of America (IDSA) has established practice guidelines for treatment of community-acquired pneumonia (CAP), but these guidelines require frequent updates to accommodate the rapid changes in the field. Thus, the 2000 treatment guidelines (1) were updated in 2003 (2) and another update is scheduled for 2005. The purpose of the present report is to summarize the most recent guidelines of the IDSA for CAP with particular attention to the role of levofloxacin.